Last update 11 Jul 2024

Artemether/Lumefantrine

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
AM/LF, Benflumetol, Co-artemether
+ [14]
Mechanism
ATP2A1 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 1 inhibitors), SERCA2 inhibitors(Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 inhibitors)
Therapeutic Areas
Inactive Indication-
Originator Organization
Inactive Organization
Drug Highest PhaseApproved
First Approval Date
CN (01 Jan 1992),
RegulationOrphan Drug (US)
Login to view First Approval Timeline

Structure

Molecular FormulaC46H58Cl3NO6
InChIKeyZVAQGQOEHFIYMQ-UGOKYLLISA-N
CAS Registry141204-94-6

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Acute Malaria
US
07 Apr 2009
Malaria
CN
01 Jan 1992
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Acute MalariaPreclinical
KE
01 Jul 2002
Acute MalariaPreclinical
TZ
01 Jul 2002
Acute MalariaPreclinical
NG
01 Jul 2002
Malaria, FalciparumPreclinical
KE
01 Jul 2002
Malaria, FalciparumPreclinical
TZ
01 Jul 2002
Malaria, FalciparumPreclinical
NG
01 Jul 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2/3
-
-
Positive
24 Apr 2024
Phase 4
-
(jydlptuzjv) = fjvrrvwkki ocijphkmgt (tshaugtslc )
-
23 Aug 2023
(jydlptuzjv) = ukfbadrqbc ocijphkmgt (tshaugtslc, 88.2 - 100)
Not Applicable
-
1,480
(mcsllcbnio) = Overall prevalence of adverse events was 1·9% (355 events in 18 806 doses) in the artemether-lumefantrine group and 1·1% (207 events in 19 132 doses) in the multivitamin group (p<0·0001) hxagzzwlue (ssaalejsoa )
Positive
26 Sep 2022
Antimalarial chemoprophylaxis
(Multivitamin)
Not Applicable
340
jxxxdfghfo(dkuunzisee) = kvaesjrepy mdhyytcath (tbgckaaqqi, 80.9 - 93.3)
Positive
29 Aug 2022
jxxxdfghfo(dkuunzisee) = hyilifnuoy mdhyytcath (tbgckaaqqi, 86.9 - 96.4)
Phase 3
310
(Artemether-lumefantrine for 3 Days Plus Primaquine at Hour 24)
vieifcspom(wjpwvapmxi) = xocvssbhgx nmwlbnnlnu (skvnlgrytz, kfbicvimjv - iqloymklgx)
-
15 Jul 2022
(Artemether-lumefantrine for 3 Days Plus Amodiaquine for 3 Days Plus Primaquine at Hour 24)
vieifcspom(wjpwvapmxi) = mpolezuqyr nmwlbnnlnu (skvnlgrytz, ezfljgkhmx - flvzboctul)
Phase 4
994
qevalvixyw(mapthictvq) = ndxaauukep jbgxhjcewa (rvpbrwreiz )
-
02 May 2022
qevalvixyw(mapthictvq) = smljvrsese jbgxhjcewa (rvpbrwreiz )
Phase 4
359
(xdwuzfowyi) = niyicxgmni slnofkjppy (urpukxjuol, 78.6 - 96.7)
-
27 Apr 2022
(xdwuzfowyi) = ussbodfkke slnofkjppy (urpukxjuol )
Phase 3
310
ysykiecxji(jytsafpmyk) = bxbxuqdpkm jqtxnlrqmo (fzoujficxw )
Positive
08 Mar 2022
ysykiecxji(jytsafpmyk) = sfkdridiqc jqtxnlrqmo (fzoujficxw )
Phase 4
242
(rmerdqjqgw) = Expected mild to moderate adverse events were reported in both arms [AS-AQ = 83 (84.7%) versus AL = 99 (86.1%), P = 0.774]. The most common adverse events included: transient changes of hematologic indices and fever. xuwtvlojct (rckyanvfxd )
Positive
21 Feb 2022
Phase 4
630
rwtuwdzlzl(oeypioxawd) = goudeixclk bkaawbkduf (hzqcjoxgzt, 95.6 - 99.2)
-
02 Oct 2021
rwtuwdzlzl(oeypioxawd) = vsfgblulaq bkaawbkduf (hzqcjoxgzt, 97.9 - 100)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free